

Taflopust Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 558015-00021 Date of last issue: 12/13/2025
Date of first issue: 03/15/2016

SECTION 1. IDENTIFICATION

Product name : Taflopust Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Glycerine	1,2,3-Propanetriol	56-81-5*	>= 1 - <= 5	TSC
Taflopust	No data available	209860-87-7*	> 0 - <= 0.1	TSC

* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.
In case of eye contact : Flush eyes with water as a precaution.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/13/2025
4.0	05/09/2026	558015-00021	Date of first issue: 03/15/2016

If swallowed	:	Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	None known.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for	:	Soak up with inert absorbent material.

Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/13/2025
4.0	05/09/2026	558015-00021	Date of first issue: 03/15/2016

containment and cleaning up For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Glycerine	56-81-5	TWA (Mist)	10 mg/m ³	CA AB OEL
		TWA (Mist)	10 mg/m ³	CA BC OEL
		TWA (Respirable mist)	3 mg/m ³	CA BC OEL
		TWAEV (Mist)	10 mg/m ³	CA QC OEL
Tafluprost	209860-87-7	TWA	0.002 µg/m ³ (OEB 5)	Internal
Further information: Skin, Eye				
		Wipe limit	0.02 µg/100 cm ²	Internal

Engineering measures : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine

Tafluprost Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 558015-00021 Date of last issue: 12/13/2025
Date of first issue: 03/15/2016

appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Organic vapor Type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Tafluprost Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 558015-00021 Date of last issue: 12/13/2025
Date of first issue: 03/15/2016

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Aqueous solution
Color	:	clear
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/13/2025
4.0	05/09/2026	558015-00021	Date of first issue: 03/15/2016

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Glycerine:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

Tafluprost:

Acute oral toxicity : LD50 (Rat): 665 mg/kg
LD50 (Rat): > 100 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : (Dog): 3 mg/kg
Application Route: Intravenous
Target Organs: Cardio-vascular system

Skin corrosion/irritation

Not classified based on available information.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Tafluprost Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 558015-00021 Date of last issue: 12/13/2025
Date of first issue: 03/15/2016

Components:

Glycerine:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Glycerine:

Species : Rabbit
Result : No eye irritation

Tafluprost:

Species : Monkey
Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Tafluprost:

Test Type : Maximization Test
Routes of exposure : Dermal
Species : Guinea pig
Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Glycerine:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Tafluprost Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 558015-00021 Date of last issue: 12/13/2025
Date of first issue: 03/15/2016

||

Tafluprost:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Glycerine:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Tafluprost:

Species : Rat
Application Route : Subcutaneous
Exposure time : 24 Months
Result : negative

Species : Mouse
Application Route : Subcutaneous
Exposure time : 18 Months
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Glycerine:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Taf luprost Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 558015-00021 Date of last issue: 12/13/2025
Date of first issue: 03/15/2016

Taf luprost:

- Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 100 µg/kg
Result: No effects on fertility.
- Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 10 µg/kg
Result: Malformations were observed., Reduced fetal weight.
- Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 3 µg/kg
- Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 0.03 µg/kg
Result: Malformations were observed.
- Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 0.01 µg/kg
- Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 1 µg/kg
- Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 0.3 µg/kg
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

Components:

Taf luprost:

- Target Organs : Lungs, Cardio-vascular system
Assessment : Causes damage to organs.

STOT-repeated exposure

Not classified based on available information.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Tafluprost Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 558015-00021 Date of last issue: 12/13/2025
Date of first issue: 03/15/2016

Components:

Tafluprost:

Target Organs : Lungs, Cardio-vascular system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Glycerine:

Species : Rat
NOAEL : 0.167 mg/l
LOAEL : 0.622 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 13 Weeks

Species : Rat
NOAEL : 8,000 - 10,000 mg/kg
Application Route : Ingestion
Exposure time : 2 y

Species : Rabbit
NOAEL : 5,040 mg/kg
Application Route : Skin contact
Exposure time : 45 Weeks

Tafluprost:

Species : Rat
LOAEL : 0.01 mg/kg
Application Route : Intravenous
Exposure time : 6 Months
Target Organs : Cardio-vascular system, Blood, Bone marrow, Kidney, Liver, spleen

Species : Dog
NOAEL : 0.0001 mg/kg
LOAEL : 0.001 mg/kg
Application Route : Intravenous
Exposure time : 39 Weeks
Target Organs : Cardio-vascular system, Eye
Symptoms : Dilatation of the pupil

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Tafluprost:

Eye contact : Symptoms: dryness of the eyes, Blurred vision

Tafluprost Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 558015-00021 Date of last issue: 12/13/2025
Date of first issue: 03/15/2016

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Glycerine:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l
Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8

Persistence and degradability

Components:

Glycerine:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 92 %
Exposure time: 30 d
Method: OECD Test Guideline 301D

Bioaccumulative potential

Components:

Glycerine:

Partition coefficient: n-octanol/water : log Pow: -1.75

Tafluprost:

Partition coefficient: n-octanol/water : log Pow: 4.5

Mobility in soil

No data available

Other adverse effects

No data available

Endocrine disrupting properties

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/13/2025
4.0	05/09/2026	558015-00021	Date of first issue: 03/15/2016

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

CN IECSC : not determined

Canadian lists

No substances are subject to CEPA Section 84 Ministerial Conditions.

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for air-borne contaminants

CA AB OEL / TWA : 8-hour Occupational exposure limit

CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWA EV : Time-weighted average exposure value

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Taf luprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/13/2025
4.0	05/09/2026	558015-00021	Date of first issue: 03/15/2016

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/09/2026
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET
according to the Hazardous Products Regulations



Tafluprost Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/13/2025
4.0	05/09/2026	558015-00021	Date of first issue: 03/15/2016

CA / Z8